EPO modulates CEBPA expression in a dose-dependent manner in liver-derived cells. qRT-PCR assessment of CEBPA (A) and Cebpa (B) mRNA expression in HepG2 cells and in mouse hepatocytes treated with rEPO (▒, left) and/or anti-EPOR (□ and ■, respectively) and IL-6 (▒, right). Untreated cells were used as control (▫, left). Figure represents the average + SD of 3 independent experiments for HepG2 cells. A total of 7 animals were used for each mouse hepatocyte treatment; * denotes a significant difference (P < .05) between EPO(+)/anti-EPOR(−) or EPO(−)/anti-EPOR(+) or EPO(−)/anti-EPOR(+)/Block(+) or IL6(+) and the EPO(−)/anti-EPOR(−) control (one-way ANOVA). ** stands for a significant difference (P < .05) between EPO(+)/anti-EPOR(+) or EPO(1 U)/anti-EPOR(+)/Block(+) and the EPO(1 U)/anti-EPOR(−) control (2-way ANOVA).